© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Robert Holloway, MD, presents a patient case of metastatic endometrial cancer and discusses the systemic therapy options and recommended guidelines in this setting.
January 19th 2023
Robert Holloway, MD, presents the diagnosis and treatment regimen of a 71-year-old woman with mismatch repair-proficient (pMMR) metastatic endometrial cancer.
Dr Robert Holloway describes the presentation of a typical patient with metastatic endometrial cancer, and whether all patients receive MMR testing.
An expert details the currently available systemic therapies for patients with MMR-proficient metastatic endometrial cancer who experienced recurrent disease after platinum-based chemotherapy.
Robert Holloway, MD, review safety and efficacy data from a clinical trial investigation of lenvatinib combined with pembrolizumab for the treatment of advanced endometrial cancer.
Dr Robert Holloway explains what second-line treatment regimen he would have chosen for the patient with metastatic endometrial cancer in the presented case.
Insights into the goals of second-line therapy for patients with advanced/recurrent endometrial carcinoma, and best strategies for adverse event management.
Robert Holloway, MD, highlights the issue of racial disparity in endometrial cancer, and the critical unmet needs for patients.